A Phase 2 interventional study of Budiodarone 200 mg BID and Budiodarone 400 mg BID in Atrial Fibrillation (AF) and Paroxysmal AF, sponsored by Xyra, LLC. Recruiting at 4 sites in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Xyra, LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Atrial Fibrillation with a site in Poland — 32 open to participants now, 45 under way, 2 of them phase 3. Atrial Fibrillation · Poland.
Among the 149 studies in Atrial Fibrillation with a site in Poland, this one is the 80th largest by planned enrollment of the 102 interventional ones that give a count, is one of 7 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 25 of the 44 other live ones, and was the 145th registered.
4,016 studies on the registry are indexed under Atrial Fibrillation; 964 are open to participants now.
Browse Atrial Fibrillation studies →32 of the 149 studies in Atrial Fibrillation with a site in Poland are open now. Recruiting first, the newest first:
Bayer · Sites in Poland, United States, Belgium and 5 more countries
Ages 18–85
Mitera Hospital · Sites in Poland, Croatia, Czechia and 5 more countries
Ages 18+
Abbott Medical Devices · Sites in Poland, Belgium, Czechia and 7 more countries
Ages 18+
Wroclaw Medical University · Sites in Poland
Ages 18+
Medical University of Silesia · Sites in Poland
Ages 18–75
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 610 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 17 · Phase 3 38 · Phase 4 14
First in 1999; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 2,479 interventional studies indexed under Atrial Fibrillation.
Median enrollment 327 across the 102 interventional studies, 500 across the 44 observational. Of the 83 that completed or were terminated, 35 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 149 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Xyra, LLC as lead sponsor.
Xyra, LLC has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
15 of the studies in Atrial Fibrillation with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT05005949Medtronic Cardiac Ablation SolutionsSTOP Persistent AF PAS | 2026-12 |
| NCT07809347Wroclaw Medical UniversityEvaluation of the Factors Associated With BRADYcardia Following Pulmonary Vein Isolation Using Pulsed Field Ablation | 2026-12-31 |
| NCT06355063Pulse Biosciences, Inc.CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation | 2026-12-31 |
| NCT05305612National Institute of Cardiology, Warsaw, PolandOptimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions | 2027-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 149 studies in Atrial Fibrillation with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label study aims to assess the safety, tolerability and efficacy of budiodarone in treating participants with non-permanent AF, in particular paroxysmal atrial fibrillation (PAF). The trial will serve as a 6-month safety and a proof-of-concept study for a dose escalation strategy using AF monitoring, enrolling approximately 100 participants who will undergo 24 weeks of treatment. The study aims to evaluate the feasibility of dose escalation through AF monitoring of long episodes atrial fibrillation last 5 hours or longer.
The study will allow AF participants from three specific populations: 1) Participants with a pre-implanted Cardiac Implantable Electrical Device (CIED), which includes implantable pacemakers or implantable loop recorders (ILR) and who have a history of paroxysmal AF with LEAF lasting 5 hours or longer recorded in their pacemaker within the 3 months before screening; 2) Participants undergoing first-time elective electrical (direct current) cardioversion for persistent AF, or second-time elective electrical (direct current) cardioversion; and 3) Participants with paroxysmal AF who do not have a pacemaker or ILR and who have a history of frequent AF and LEAF, with a minimum CHA2DS2-VASc score of 1 or more for males and 2 or more for females.
AF monitoring will be conducted via a pre-implanted Cardiac Implantable Electrical Device (CIED), which includes implantable pacemakers or implantable loop recorders (ILR), for those who have one. Participants without a CIED will undergo AF monitoring using a cardiac patch and/or a wearable device on the wrist.
All participants who meet the study entry criteria will be started on 200 mg budiodarone BID. The participants will return to the study site every 4 weeks and dose adjustments will follow the following algorithm. If no AF episode lasting 5 hours or longer is recorded and no rolling 24-hour period shows a cumulative AF burden of 5 hours or longer, the participant is classified as a monthly responder, and the budiodarone dose remains unchanged. If at least one AF episode of 5 hours or longer is observed, or if any rolling 24-hour period indicates a cumulative AF burden of 5 hours or longer, the participant is designated as a monthly non-responder, and the budiodarone dose is increased by 200 mg BID up to a maximum of 800 mg BID.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Budiodarone is formulated as 200 mg capsules, to be administered as 1 capsule (200mg) twice a day (BID), 2 capsules (400 mg) BID, 3 capsules (600 mg) BID or 4 capsules (800 mg) BID.
Drug: Budiodarone 200 mg BID · Drug: Budiodarone 400 mg BID · Drug: Budiodarone 600 mg BID · Drug: Budiodarone 800 mg BID
Budiodarone is formulated as 200 mg capsules, to be administered as 1 capsule (200mg) twice a day (BID).
Budiodarone is formulated as 200 mg capsules, to be administered as 2 capsules (400 mg) BID.
Budiodarone is formulated as 200 mg capsules, to be administered as 3 capsules (600 mg) BID.
Budiodarone is formulated as 200 mg capsules, to be administered as 4 capsules (800 mg) BID.
Proportion of participants that have no long episodes of atrial fibrillation (LEAF) in the final month of treatment
Proportion of participants that have no LEAF (uninterrupted episode of AF of 5 hours or longer in duration or cumulative duration of AF in any rolling 24-hour period that is 5 hours or longer) in the final month of treatment.
Time frame: 24 weeks
Percent Change in Atrial Fibrillation Burden (AFB)
Percent change in AFB during final month of treatment compared to baseline.
Time frame: 24 weeks
Change in percent of Atrial Fibrillation Severity Scale (AFSS) during final month of treatment.
The University of Toronto Atrial Fibrillation Severity Scale (AFSS) is a patient-reported outcome instrument developed to quantify atrial fibrillation (AF). In this study, Part C of the scale will be used. In Part C, participants are asked to asses how AF symptoms affect daily activities, physical functioning, and overall quality of life. The minimum score is 0 and the maximum score is 35. Higher scores reflect greater impairment from AF-related symptoms. AFSS score during final month of treatment will be compared to baseline for multiple doses of budiodarone.
Time frame: 24 weeks
Patient Global Impression of Change (PGI-C) during the final month of treatment
The Patient Global Impression of Change (PGI-C) is a two-question instrument that employs a Likert scale to assess participants' perceived changes in AF symptom control and overall satisfaction. Response options for symptom control include: Made them worse, No change, Slight improvement, Moderate improvement, A lot of improvement, and Complete relief. For overall satisfaction, participants choose from: Not at all, A little bit, Somewhat, A lot, and Completely.
Time frame: 24 weeks
Safety Assessment
Incidence of treatment-emergent adverse events (TEAE) and treatment-emergent serious adverse events (TESAE)
Time frame: 24 weeks
Safety Assessment
Incidence of adverse events of special interest (AESI)
Time frame: 24 weeks
Safety Assessments
Incidence of death
Time frame: 24 weeks
Safety Assessment
Incidence of resuscitated sudden cardiac death
Time frame: 24 weeks
Safety Assessment
Incidence of cardiovascular hospitalization
Time frame: 24 weeks
Safety Assessment
Incidence of stroke
Time frame: 24 weeks
The proportion of participants with no LEAF episodes lasting one hour or longer in the final month of budiodarone treatment
The proportion of participants with no LEAF episodes lasting one hour or longer in the final month of budiodarone treatment
Time frame: 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 10 months after the start.
Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.